| Literature DB >> 35412348 |
Caitlin Pley1,2, José Lourenço3,4, Anna L McNaughton5,6, Philippa C Matthews6,7,8.
Abstract
Hepatitis B virus (HBV) polymerase is divided into terminal protein, spacer, reverse transcriptase, and RNase domains. Spacer has previously been considered dispensable, merely acting as a tether between other domains or providing plasticity to accommodate deletions and mutations. We explore evidence for the role of spacer sequence, structure, and function in HBV evolution and lineage, consider its associations with escape from drugs, vaccines, and immune responses, and review its potential impacts on disease outcomes.Entities:
Keywords: HBV; diversity; evolution; genotype; hepatitis B virus; phylogeny; polymerase; polymorphism; spacer
Mesh:
Substances:
Year: 2022 PMID: 35412348 PMCID: PMC9093120 DOI: 10.1128/jvi.00051-22
Source DB: PubMed Journal: J Virol ISSN: 0022-538X Impact factor: 6.549
FIG 1Genomic and functional roles of HBV spacer domain. (A) Structure of overlapping ORFs in the HBV 3.2-kb partially double-stranded circular genome. The entire length of surface (S) (400 aa) is encoded on an alternate frame within the length of Polymerase (P), making it the longest known overlap of any animal virus. (B) HBV P polyprotein, showing subdomains TP (terminal protein), spacer, RT (reverse transcriptase), and RNase H. (C) Model to illustrate overlapping reading frames (ORF) with different codon usage by overlapping genes and modular evolution theory due to imprinting. (D) Annotation of spacer domain (165 aa), illustrating examples of sequence polymorphisms associated with lineage (genotype), enzymatic function, and key functional outcomes. Deletions are best tolerated in the N-terminal 2/3 of the protein, while the C-terminal 1/3 contains the majority of residues with established functional roles. Numbering and sequence are based on genotype A reference genome accession no. X02763. Cysteine residues in the putative zinc finger DNA-binding motif are marked with a star at aa 325, 336, and 340 (equating to previously described positions 312, 323, and 327 in a genotype D strain). Coloured underlining of the sequence matches the annotation in the schematic lay-out above, as follows: turquoise, gtA; green, gtD; red, gtE; purple, B cell epitope; pink, key regions in C-terminus.
FIG 2Nucleotide pairwise distances within and between genotypes in HBV polymerase. Representative HBV genotype sequences for genotypes A to I (129) were analyzed using a sliding window size of 100 bp and increments of 25 bp in SSE v1.3 (130). Putative genotype J was excluded, as regions of the genotype are thought to originate from nonhuman HBV sequences.
Examples of evidence that spacer residues can be used to distinguish between HBV genotypes, subgenotypes, and geographic distribution of lineages
| HBV genotype | Location | Observation(s) | Reference |
|---|---|---|---|
| A, subgenotype A1 | Brazil | Four amino acids in the polymerase, of which two (Pro18 and His90) are in spacer, and one in the core antigen were sufficient to determine sequence clustering with isolates from Asia but not with A1 isolates from Southern and East Africa |
|
| These five amino acids supported Bayesian analysis, concluding that the Brazilian isolates formed part of the Asian-American clade of subgenotype A1 (posterior probability value, 0.996). | |||
| A, subgenotype A1 | Zimbabwe | Characteristic shared residues in PreS1, PreS2, and spacer associated with clustering of sequences as part of the South African A1 clade |
|
| Spacer was relatively well conserved among the Zimbabwean isolates | |||
| Two spacer motifs (Ser9Gln10 and Glu18Ser19Phe20) could distinguish Zimbabwean isolates from clades found in other African and Asian countries where HBV/A1 is endemic but were shared with the South African HBV/A1 clade | |||
| B and C | China | Genotype-specific mutations that distinguished genotypes B and C were found to be nonrandomly clustered in spacer |
|
| 56 of the 85 genotype-specific mutations were distributed in the 5′ half of the P/S overlap, of which 42 mutations led to amino acid changes in spacer, and 23 mutations caused amino acid changes in PreS | |||
| Only 29 mutations were present in the 3′ half of the overlapping reading frame, of which 13 caused residue changes in RT and 18 caused residue changes in S | |||
| D, subgenotype D1/D4 | Russia and the Baltic | Amino acids 58–128 of spacer contain subgenotype-specific mutations capable of reliably differentiating between D1 and D4 isolates |
|
| E | West Africa | Despite low intragenotype diversity of genotype E, the spacer region contained eight unique amino acid residues (Glu16, His21, Arg52, Asp55, Met64, Lys88, Asn110, and His111) |
|
| A conserved genotype-specific signature motif was also discovered in PreS1 | |||
| Multiple | All | Deletions at the start of spacer (predicted to start at nt 2856 in the |
|
| Known conserved deletions in PreS1, Δ2861–3 in genotypes E and G, and Δ2854–2886 in genotypes D and J result in deletions at the start of spacer |
Locations of the residues are given by numbering the start of the spacer domain as the first amino acid.
Summary of HBV mutagenesis studies in spacer and the resultant phenotype
| Virus | Spacer residues | Phenotype | Reference |
|---|---|---|---|
| Deletions | |||
| HBV | aa 175–300 | No ability to engage in RNA binding, RNA packaging, or protein priming |
|
| HBV | aa 178–336 | Reduced polymerase activity (70% of WT) |
|
| HBV | aa 179–257 | No impact on replication capacity and RNA encapsidation |
|
| HBV | aa 196–291 | Increased expression; decreased protein priming ability |
|
| HBV | aa 199–300 | Incapable of RNA packaging; able to bind RNA and perform protein priming |
|
| HBV | aa 201–292 | Decreased polymerase activity (40% of WT) |
|
| HBV | aa 201–292 | Decreased polymerase activity (40% of WT); no impact on RNA packaging |
|
| HBV | aa 201–335 | Impaired polymerase activity (<0.3% of WT) |
|
| HBV | aa 258–286 | Capable of RNA encapsidation |
|
| HBV | aa 258–336 | Incapable of replication and RNA encapsidation |
|
| HBV | aa 287–317 | Incapable of RNA encapsidation |
|
| HBV | aa 293–335 | Impaired polymerase activity (<0.3% of WT) |
|
| HBV | aa 293–335 | Impaired polymerase activity (<0.5% of WT); decrease in RNA packaging efficiency |
|
| HBV | aa 300–334 | Impaired priming function |
|
| HBV | aa 318–336 | Incapable of RNA encapsidation |
|
| HBV | nt 2878–129 | Increased stability of the P protein |
|
| DHBV | aa 307–356 | No impact on polymerase activity |
|
| Substitutions | |||
| HBV | C312A, C323A, C327A, C341A | Each mutation individually is incapable of RNA binding, RNA packaging, and protein priming |
|
| HBV | C312A, C323A, C327A | Each mutation individually is incapable of RNA encapsidation |
|
| HBV | C326R | No detectable replication activity |
|
| HBV | E245L | Reduced but still significant level of replication |
|
| HBV | R219S, R246G, G261R, N270S, A272S, R300H | Decreased replication efficiency |
|
| Insertions | |||
| DHBV | Bacterial protein A inserted into spacer | No impact on DNA synthesis and RNA packaging activities |
|
| DHBV | 12 nt at 1,212 bp (in frame) | No impact on replication capacity |
|
| DHBV | 4 nt at 1,212 bp (frameshift) | Impaired replication capacity |
|
The majority of studies were in human HBV, with a small number also carried out using duck HBV (DHBV) as an animal model. Polymorphism locations are provided as cited in the primary studies, which may differ from reference genotype A sequence X02763. aa, amino acid residue; nt, nucleotide; bp, base pairs; WT, wild type.